Clinical Trial Update: Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis [Phase 3]

View source ↗

Summary

Phase 3 trial update on arbaclofen placarbil for spasticity in multiple sclerosis reports efficacy and safety data.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Arbaclofen placarbil (arbaclofen placarbil)

Snippet

Sponsor: XenoPort, Inc. | Conditions: Multiple Sclerosis | Phase 3 | Status: COMPLETED